Statin use and cancer risk in the General Practice Research Database

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 635-637

  Kaye, J A ^a,b   Jick, H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A inhibitors; Epidemiology; Hyperlipidaemia; Statins

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; STATIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; COLON CANCER; COLON TUMOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DIGESTIVE SYSTEM CANCER; FACTUAL DATABASE; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LUNG CANCER; MALE; MELANOMA; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; RISK FACTOR; URINARY TRACT CANCER;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROSTATIC NEOPLASMS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 1542329169     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601566     Document Type: Article

References (19)

1. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93
2. Beck P, Wysowski KD, Downey W, Butler-Jones D (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56: 280-285
3. Bjerre LM, LeLorier J (2001) Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110: 716-723
4. Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. A nested case-control study. Arch Intern Med 160: 2363-2368
5. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13: 262-267
6. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S (2002) Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4: 337-346
7. Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278: 313-321
8. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 302: 766-768
9. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium-channel blockers and risk of cancer. Lancet 349: 525-528
10. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the General Practice Research Database. Pharmacotherapy 23: 686-689
11. Kaye JA, Derby LE, Melero-Montes MM, Quinn M, Jick H (2000) The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data. Br J Cancer 83: 1556-1558
12. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H (2002) 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317
13. Muller C, Bockhorn AG, Klusmeier S, Kiehl M, Roeder C, Kalthoff H, Koch OM (1998) Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 12: 717-723
14. Newman TB, Hulley SB (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275: 55-60
15. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150
16. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105: 2341-2346
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009
18. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745
19. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519